NCT07263178招募中不适用
A Multi-center, Prospective, Observational Study to Assess the Treatment Patterns and Prognosis of Second and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer Who Failed First-line Palliative Chemotherapy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line palliative chemotherapy and to evaluate the prognosis of each treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have signed the informed consent after receiving information about the purpose and method of this study.
- •Patients with histologically and radiologically confirmed metastatic colorectal cancer (colorectal cancer) who have evaluable (measurable) lesions.
- •Patients scheduled to receive their first second-line palliative chemotherapy following failure of first-line palliative chemotherapy (including those who relapse during or within 6 months after completion of postoperative adjuvant therapy, necessitating palliative chemotherapy).
- •Patients who understand the research, are cooperative in the research process, and are deemed capable of participating until the completion date.
排除标准
- •Female patients who are pregnant, have childbearing potential, or are breastfeeding.
- •Has received an investigational product within 4 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
- •Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.
结局指标
主要结局
Progression-free survival (PFS)
时间窗: up to 24 months
Progression-free survival (PFS) by treatment pattern
次要结局
- Objective Response Rate (ORR)(up to 24 months)
- Types of Third palliative chemotherapy(up to 24 months)
- Conversion rate(up to 24 months)
- Quality of Life Assessment(up to 12 months)
- Overall Survival (OS)(up to 24 months)
- Dosage period for each treatment pattern(up to 24 months)
- Types of Secondary palliative chemotherapy(up to 24 months)
- Eastern Cooperative Oncology Group Performance Status(ECOG PS) Assessment(up to 24 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and PharmacokineticsNCT07260500Changchun GeneScience Pharmaceutical Co., Ltd.72
尚未招募
不适用
A Nationwide Multicenter, Single-arm, Retrospective Study of Delayed Endoscopic DTI-BR After Simple MastectomyBreast CancerNCT07257003Du Zhenggui150
招募中
3 期
A study to evaluate the efficacy and safety of Clascoterone solution in treatment of male pattern hair loss.Androgenetic Alopecia2023-504421-39-00Cassiopea S.p.A.629
招募中
1 期
Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.Eosinophilic esophagitis2024-512722-28-00Bioprojet Pharma161
招募中
1 期
A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS2023-504746-54-00Tranquis Therapeutics Inc.16